1)Sato S, et al:Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum 52:1571-1576, 2005
2)Hoshino K, et al:Anti-MDA5 and anti-TIF1-g antibodies have clinical significance for patients with dermatomyositis. Rheumatology(Oxford)49:1726-1733, 2010
3)Kang EH, et al:Myositis autoantibodies in Korean patients with inflammatory myositis;Anti-140-kDa polypeptide antibody is primarily associated with rapidly progressive interstitial lung disease independent of clinically amyopathic dermatomyositis. BMC Musculoskelet Disord 11:223, 2010
4)Suzuki Y, et al:Intravenous immunoglobulin therapy for refractory interstitial lung disease associated with polymyositis/dermatomyositis. Lung 187:201-206, 2009
5)Peek GJ, et al:Efficacy and economic assessment of conventional ventilatory support versus extracorporeal membrane oxygenation for severe adult respiratory failure(CESAR);A multicentre randomised controlled trial. Lancet 374:1351-1363, 2009
6)Zong M, Lundberg IE:Pathogenesis, classification and treatment of inflammatory myopathies. Nat Rev Rheumatol 7:297-306, 2011